Rewiring aberrant cancer signaling to a therapeutic effector response with a synthetic two-component system
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsHokyung Chung, Michael Z. Lin
Life of this patent
Estimating the term…
Abstract
Compositions and methods for targeted treatment of cancer are disclosed. In particular, the invention relates to methods of targeting anti-cancer therapy to cells exhibiting aberrant signaling associated with cancer pathogenesis by administering synthetic signaling proteins that couple detection of an oncogenic signal to release of therapeutic agents into cancerous cells.
Claims36
A vector system comprising one or more viral vectors comprising:
- a) a first expression cassette encoding a first fusion protein comprising a protease connected to a phosphotyrosine binding (PTB) domain capable of binding to a first constitutively phosphorylated tyrosine residue on an endogenous hyperactive receptor tyrosine kinase;
- and
- b) a second expression cassette encoding a second fusion protein comprising a sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:21, and SEQ ID NO:22, or a sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:21, and SEQ ID NO:22.
A vector system comprising a viral vector comprising a sequence selected from the group consisting of SEQ ID NO:23 and SEQ ID NO:24, or a sequence having at least 90% identity to the sequence selected from the group consisting of SEQ ID NO:23 and SEQ ID NO:24.
Dependencies are inferred from the claim text.